Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression

Journal of Clinical Endocrinology and Metabolism

Volumn 81, Issue 3, 1996, Pages 914-918

  Cordido, Fernando ^a   Peino, Roberto ^a   Peñalva, Angela ^a   Alvarez, Clara V ^a   Casanueva, Felipe F ^a   Dieguez, Carlos ^a,b  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACIPIMOX; FATTY ACID; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; HISTIDYL DEXTRO TRYPTOPHYLALANYLTRYPTOPHYL DEXTRO PHENYLALANYLLYSINAMIDE; PLACEBO; PYRIDOSTIGMINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FATTY ACID BLOOD LEVEL; FEMALE; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HUMAN; MALE; OBESITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTILIPEMIC AGENTS; FATTY ACIDS, NONESTERIFIED; FEMALE; GROWTH HORMONE; GROWTH HORMONE-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; OBESITY; OLIGOPEPTIDES; PYRAZINES; PYRIDOSTIGMINE BROMIDE;

EID: 0029935185     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.81.3.914     Document Type: Article

References (28)

1. Copinschi G, Wegienka LC, Hane S, Forsham PH. 1967 Effect of arginine on serum levels of insulin and growth hormone in obese subjects. Metabolism. 16:485-491.
2. Sims EAH, Danforth E, Horton ES, et al. 1973 Endocrine and metabolic effects of experimental obesity in man. Recent Prog Horm Res. 29:457-496.
3. Glass AR, Burman KD, Dahms WT, Bohem TM. 1981 Endocrine function in human obesity. Metabolism. 30:89-104.
4. Muruais C, Cordido F, Morales MJ, Casanueva FF, Dieguez C. 1991 Corticosteroid-induced growth hormone secretion in normal and obese subjects. Clin Endocrinol (Oxf). 35:485-490.
5. Dieguez C, Casanueva FF. 1995 Influence of metabolic substrates and obesity on growth hormone secretion. Trends Endocrinol Metab. 6:55-59.
6. Williams T, Berelowitz M, Joffe SN, et al. 1984 Impaired growth hormone responses to growth hormone releasing factor in obesity. N Engl J Med. 311:1403-1407.
7. Massara F, Ghigo E, Molinati P, et al. 1986 Potentiation of cholinergic tone by pyridostigmine bromide re-instates and potentiates the growth hormone responsiveness to intermittent administration of growth hormone releasing factor in man. Acta Endocrinol (Copenh). 113:12-16.
8. Peñalva A, Muruais C, Casanueva FF, Dieguez C. 1990 Effect of enhancement of endogenous cholinergic tone with pyridostigmine on the dose-response relationships of growth hormone-releasing hormone-induced growth hormone secretion in normal subjects. J Clin Endocrinol Metab. 70:324-328.
9. Cordido F, Dieguez C, Casanueva FF. 1990 Effect of central cholinergic neurotransmission enhancement by pyridostigmine on the growth hormone secretion elicited by clonidine, arginine, or hypoglycemia in normal and obese subjects. J Clin Endocrinol Metab. 70:1361-1370.
10. Cordido F, Casanueva FF, Dieguez C. 1989 Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects. J Clin Endocrinol Metab. 68:290-293.
11. Cordido F, Peñalva A, Dieguez C, Casanueva FF. 1993 Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity. J Clin Endocrinol Metab. 76:819-823.
12. Bowers CY, Momany FA, Reynolds GA, Hong A. 1984 On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 114:1537-1545.
13. Golay A, Swislocki ALM, Chen Y-DI, Jaspan JB, Reaven GM. 1986 Effect of obesity on ambient plasma glucose, free fatty acid, insulin, growth hormone and glucagon concentrations. J Clin Endocrinol Metab. 63:481-484.
14. Irie M, Sakuma M, Tsushima T, Shizume K, Nakao K. 1967 Effect of nicotinic acid administration on plasma growth hormone concentrations. Proc Soc Exp Biol Med. 126:708-711.
15. Fuccella L, Goldaniga G, Lovisolo P. 1980 Inhibition of lipolysis by nicotinic acid and acipimox. Clin Pharmacol Ther. 28:790-795.
16. Pontiroli AE, Lanzi R, Monti LD, Pozza G. 1990 Effect of acipimox, a lipid lowering drug on growth hormone (GH) response to GH-releasing hormone in normal subjects. J Endocrinol Invest. 13:539-542.
17. Pontiroli AE, Lanzi R, Monti LD, Sandoli E, Pozza G. 1991 Growth hormone (GH) auto feedback on GH response to GH-releasing hormone. Role of tree fatty adds and somatostatin. J Clin Endocrinol Metab. 72:492-495.
18. Bray GA. 1979 Obesity in America. Washington DC: U.S. Government Printing Office; NIH publication 79/359.
19. Veldhuis JD, Iranmanesh A, Ho KK, Waters MJ, Johnson ML, Lizarralde G. 1991 Dual defects in pulsatile GH secretion and clearance subserve the hyposomatotropism of obesity in man. J Clin Endocrinol Metab. 72:51-59.
20. Kelijman M, Frohman LA. 1988 Enhanced growth hormone responsiveness to GH-releasing hormone after dietary manipulation in obese and nonobese subjects. J Clin Endocrinol Metab. 66.489-494.
21. Bowers C. 1993 Editorial: a new dimension on the induced release of growth hormone in obese subjects. J Clin Endocrinol Metab. 76:817-818.
22. Casanueva FF, Villanueva L, Dieguez C, et al. 1987 Free fatty acids block growth hormone (GH) releasing hormone-stimulated GH secretion in man directly at the pituitary. J Clin Endocrinol Metab. 65:634-642.
23. Casabiell X, Pandiella A, Casanueva FF. 1991 Regulation of epidermal-growth-factor-receptor signal transduction by cis-unsaturated fatty acids. Biochem J 278:679-687.
24. Casabiell X, Zugaza JL, Pombo CM, Pandiella A, Casanueva FF. 1993 Oleic acid blocks epidermal growth factor-activated early intracellular signals without altering the ensuing mitogenic response. Exp Cell Res. 205:365-373.
25. Peino R, Cordido F, Peñalva A, Alvarez CV, Dieguez C, Casanueva FF. 1996 Acipimox-mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentiates the response to other GH releasing stimuli. J Clin Endocrinol Metab. 81:909-913.
26. Popovic V, Damjanovic S, Micic D, Djurovic M, Dieguez C, Casanueva FF. 1995 Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level. J Clin Endocrinol Metab. 80:942-947.
27. Cordido F, Peñalva A, Peino R, Casanueva FF, Dieguez C. 1995 Effects of combined administration of growth hormone (GH)-releasing hormone, GH-releasing peptide and pyridostigmine in normal and obese subjects. Metabolism. 44:745-748.
28. Alvarez CV, Mallo F, Burguera B, Cacicedo L, Dieguez C, Casanueva FF. 1991 Evidence for a direct pituitary inhibition by free fatty acids of in vivo growth hormone responses to growth hormone-releasing factor in the rat. Neuroendocrinology. 53:185-189.